Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Myositis
What were your top takeaways in Myositis from ACR Convergence 2025?
Related Questions
How do you envision incorporating CAR-T therapy into your clinical practice?
How do you approach incidental NXP-2 antibody positivity in patients without current clinical evidence of myositis or systemic autoimmune disease?
What are useful clinical features that help differentiate mechanics hands from other conditions such as hand dermatitis or psoriasis?
In a patient with newly diagnosed with antisynthetase syndrome without clinical myositis who presents with organizing pneumonia and improves on high-dose corticosteroids, what factors should guide the selection of long-term immunosuppressive therapy?
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you routinely perform muscle biopsies in patients presenting with the classic symptoms of Inclusion Body Myositis along with positive CN1A antibody?
How do you utilize tools such as MMT8 in clinical practice when evaluating myositis?
How do you approach diagnosis and management of orbital myositis?
In patients with anti-PL7 antibody–associated antisynthetase syndrome, can sacroiliitis occur as part of the inflammatory arthritis spectrum, or should alternative causes be considered?
